Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c